The field of cancer immunotherapy has seen a surge of interest in viruses engineered to selectively infect and destroy tumor cells while sparing healthy tissue. DelveInsight's "Oncolytic Virus – Competitive Landscape, 2026" report maps this evolving space in detail, covering 150+ companies and 175+ drugs in the oncolytic virus competitive landscape, with assessments by product type, stage, route of administration, and molecule type.
Oncolytic viruses are organisms able to identify, infect, and lyse different cells in the tumor environment, aiming to stabilize and decrease tumor progression. They infect abnormal cells through specific targets such as nuclear transcription factors, human telomerase reverse transcriptase, prostate-specific antigen, cyclooxygenase-2, osteocalcin, and surface markers like CD20 and Her2/neu. Researchers can also delete pathogenic viral genes in the lab to increase tumor-cell selectivity and decrease aggressiveness toward normal tissues.
Administration routes matter enormously for oncolytic virus development. Distribution can occur via intraperitoneal, intrathecal, subcutaneous, or intratumoral routes—offering greater control over viral quantity and fewer adverse effects—or intravenously, which is suited to treating distant metastases. Common viral platforms under investigation include adenoviruses, herpes simplex virus, alphaviruses, rhabdoviruses, Newcastle disease virus, and vaccinia viruses, each evaluated across multiple preclinical and clinical settings.
Regulatory and partnership activity signals growing confidence in the oncolytic virus immunotherapy market. In March 2024, ImmVira announced that the FDA had granted Fast Track designation to MVR-T3011 IT for recurrent or metastatic head and neck squamous cell cancer following platinum-based chemotherapy and prior anti-PD-1/PD-L1 therapy. Similarly, in December 2023, CG Oncology announced FDA Fast Track and Breakthrough Therapy designations for cretostimogene grenadenorepvec in BCG-unresponsive non-muscle invasive bladder cancer.
Deal-making has also accelerated. In May 2022, KaliVir Immunotherapeutics entered a global exclusive licensing collaboration with Roche to develop oncolytic vaccinia viruses derived from its VE platform, while Calidi Biotherapeutics secured a new US patent related to its SuperNova oncolytic virotherapy delivery platform and later merged with Edoc Acquisition Corp to pursue a Nasdaq listing.
A wide roster of oncolytic virus companies is driving this space forward, including Genelux Corporation, Candel Therapeutics, CG Oncology, DNAtrix, SillaJen Biotherapeutics, Oncolytics Biotech, Replimune, Transgene, Turnstone Biologics, Imugene, and many smaller biotechs spanning the US, Europe, and Asia.
SillaJen, Inc., headquartered in Seoul with offices in Busan and San Francisco, is advancing Pexa-Vec (JX-594), a Wyeth strain vaccinia virus engineered to lyse tumor cells directly while stimulating anti-tumor immunity, currently in Phase 2 for renal cell carcinoma.
Candel Therapeutics has built two viral immunotherapy platforms—adenovirus-based and HSV-based—with CAN-2409 in Phase III for prostate cancer, designed to deliver a thymidine kinase gene that activates a prodrug to kill multiplying tumor cells.
CG Oncology's lead candidate CG0070 is a modified adenovirus carrying a GM-CSF transgene, now in Phase 3 monotherapy trials for BCG-unresponsive non-muscle invasive bladder cancer, alongside combination studies with pembrolizumab and nivolumab.
Virogin Biotech's VG161, an HSV-1 construct armed with IL-12, IL-15/IL-15Rα payloads and a PD-L1 blocking peptide, is being tested with nivolumab in advanced gastric cancers, while Daiichi Sankyo's teserpaturev has already received conditional regulatory approval in Japan for malignant glioma—the first oncolytic virus approved for any primary brain cancer.
Several actively recruiting trials illustrate the breadth of ongoing investigation in the oncolytic virotherapy market. Trial "NCT05499390" recruiting patients reflects continued enrollment activity in this space, as does "NCT05214482" recruiting, both representing the kind of mid-to-late-stage studies the DelveInsight report tracks under its assessment of clinical trial status and designations. The repeated emphasis on "NCT05499390" "recruiting" status across trial registries underscores how dynamic patient enrollment remains for emerging oncolytic candidates.
DelveInsight's "Oncolytic Virus – Competitive Landscape, 2026" report maps this evolving space in detail, covering 150+ companies and 175+ drugs in the oncolytic virus competitive landscape, with assessments by product type, stage, route of administration, and molecule type.
Researchers have also explored adjunct approaches such as hydroxychloroquine oncolytic viruses cancer combination strategies, where autophagy modulation is studied alongside viral oncolysis to potentially enhance tumor cell death and immune activation. While such combinations remain largely investigational, they reflect the broader trend of pairing oncolytic platforms with existing pharmacological agents to improve therapeutic index.
Beyond traditional viral vectors, adjacent biotech innovators—including companies pursuing fusion-protein and bispecific approaches like Y Trap Inc—are exploring complementary immuno-oncology mechanisms that could eventually be paired with oncolytic platforms. Similarly, specialized players such as Y220C Therapeutics, Inc. are advancing small-molecule and targeted strategies addressing mutant p53 pathways, representing the kind of diversified oncology pipeline that often intersects with virotherapy combination research.
According to DelveInsight, key mechanisms of action across the pipeline include immunostimulants, cell death stimulants, immunologic cytotoxicity, and OX40 receptor agonists, while route-of-administration assessments span intraperitoneal, intrathecal, subcutaneous, and intratumoral delivery. The report also evaluates collaboration, licensing, and acquisition deal trends, alongside company-to-company and company-academic partnership analysis.
DelveInsight's "Oncolytic Virus – Competitive Landscape, 2026" report maps this evolving space in detail, covering 150+ companies and 175+ drugs in the oncolytic virus competitive landscape, with assessments by product type, stage, route of administration, and molecule type.
The oncolytic virus development landscape is maturing rapidly, with late-stage candidates from companies like Candel Therapeutics and CG Oncology nearing potential approval, and oncolytics biotech company players continuing to expand combination approaches with checkpoint inhibitors. As recruiting trials such as NCT05499390 and NCT05214482 progress and adjunct strategies involving hydroxychloroquine and emerging targeted-therapy players like Y Trap Inc and Y220C Therapeutics gain attention, the next several years should bring greater clarity on which platforms achieve durable clinical and commercial success in this competitive immuno-oncology niche.
DelveInsight is a leading Healthcare Business Consultant and Market Research firm exclusively focused on life sciences. We empower pharmaceutical and biotech companies with robust, end-to-end solutions for enhancing strategic decision-making and performance. Our Healthcare Consulting Services leverage market intelligence to drive growth and resolve challenges with an actionable, practical approach.
Kanishk
The digital diabetes management market is expected to reach USD 76.6 Billion by 2034, exhibiting a growth rate (CAGR) of 16.70% during 2026-2034.
Find the typical price of dental cleaning in Australia. Compare standard and deep cleaning costs, what’s included and ways to reduce your bill.
READ ARTICLEDiscover how medication for sleep, including Trazodone, Ambien, and Ketamine therapies, can help you achieve deeper, more restorative rest with physician guidance.
READ ARTICLE